Trial Profile
Randomized Phase II Trial of Irinotecan (CPT-11) In Patients With Refractory Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Sep 2006 Status change
- 17 Sep 2005 New trial record.